

AN - 1990-129058 [17]

A - [001] 014 028 035 038 04- 040 143 144 147 157 195 198 231 239 256 31-
336 344 348 359 512 525 53& 532 533 535 537 541 544 575 583 589 62-
645 688 720

AP - JP19880230936 19880914; JP19880230936 19880914; [Based on J02078629]

CPY - TAKG

DC - A96 B07

DR - 1851-U

FS - CPI

IC - A61K37/02 ; A61K47/34 ; C08G63/06 ; C08G63/08 ; C08L67/00 ; C08L77/00

KS - 0004 0005 0013 0218 0231 1279 1291 1588 1594 1840 1986 1999 2014 2148
2149 2150 2164 2177 2197 2198 2556 2575 2585 2606 2675 2766 3251

MC - A05-E09 A12-V01 B04-B02E B04-B04D3 B04-B04J B04-C01 B04-C03C B04-C03D

M1 - [01] H4 H401 H402 H481 H482 H5 H589 H8 J0 J014 J1 J171 J2 J273 M280
M311 M312 M323 M331 M332 M340 M342 M349 M381 M383 M393 M423 M431 M510
M520 M530 M540 M620 M782 M903 R051 V743; 1327-U 0502-U

- [02] M431 M782 M903 R051 V600 V613 V622 V641 V901 V902; 1327-U 0502-U

- [03] F012 F014 F423 F521 G010 G013 G100 H1 H100 H101 H181 H182 H4 H401
H441 H481 H8 J0 J011 J012 J1 J111 J171 J172 J3 J371 K0 K2 K224 L2 L250
M280 M311 M312 M313 M314 M315 M320 M321 M322 M331 M332 M333 M340 M342
M343 M349 M371 M381 M391 M392 M423 M431 M510 M520 M521 M530 M531 M540
M620 M782 M903 M904 M910 R051 V0 V621 V901 V902 V917 V922; R01851-M;
1327-U 0502-U

- [04] D011 D601 F012 F014 F423 F521 G010 G013 G100 H1 H100 H101 H181
H182 H4 H401 H441 H481 H498 H5 H598 H8 H9 J0 J011 J012 J1 J171 J172 J3
J371 K0 L2 L250 M210 M211 M271 M280 M281 M311 M312 M313 M314 M315 M320
M321 M331 M332 M333 M340 M342 M343 M349 M371 M381 M391 M423 M431 M510
M511 M520 M521 M530 M531 M540 M620 M782 M903 M904 R051 V641 V901 V902
V917 V921; R06364-M; 1327-U 0502-U

M6 - [05] M903 R051 R111 R280; 1327-U 0502-U

PA - (TAKG) TAKI CHEMICAL KK

PN - JP2078629 A 19900319 DW199017 000pp

- JP6004540B B2 19940119 DW199406 A61K37/02 005pp

PR - JP19880230936 19880914

XA - C1990-056878

XIC - A61K-037/02 ; A61K-047/34 ; C08G-063/06 ; C08G-063/08 ; C08L-067/00 ;
C08L-077/00

AB - J02078629 Medical material is based on a copolymer of (A) a
(co)polymer of lactic and/or glycolic acid and (B) polyethylene
glycol. The number average mol.wt. of component (A) is 400-5000 and
the number average mol.wt. of component (B) is 200-2000. The material
also contains a polypeptide.

- Pref. the (co)polymer of lactic and/or glycolic acid is prepd. e.g.
by dehydration-polycondensing lactic and glycolic acid directly under
reduced pressure. The lactic acid monomer is a D-, L-, or DL-body.
The copolymerisation of the lactic/glycolic copolymer with
polyethylene glycol is effected e.g. by melting the lactic/ glycolic
copolymer at 100-250 deg.C and adding polyethylene glycol.

- USE/ADVANTAGE - Base material has viscosity of 0.01-0.1 and combines
water solubility and hydrophobicity, so that its form is freely
changed by adjusting the temp. It is easily miscible uniformly with a
water-soluble polypeptide. It has good biodegradability and
biocompatibility, without side effects. The compsn. is used as a
compsn. gradually releasing drugs in the body. (7pp Dwg.No.0/0)

CN - R01851-M R06364-M